Stream One Chair

Charles L. Cooney

Charles L. Cooney

Robert T. Haslam Professor of Chemical Engineering, Emeritus, and Faculty Director, Emeritus Deshpande Center for Technological Innovation

MIT

Stream Two Co-Chair

Teresa Gorecki

Teresa Gorecki

Practice Lead

Compliance Architects LLC

Stream Three Co-Chair

Jacob Greenwood

Jacob Greenwood

Vice President Strategy

Project Farma

5:00pm - 6:00pm

Welcome Day Panel: Planning for Pharmaceutical Manufacturing of the Future: What are the Five Big Things We Need to Talk About?

Paul Testa

Paul Testa

EVP Supply Chain and Operations

Kyowa Kirin

Marian Gindy

Marian Gindy

Vice President, Small Molecule Science and Technology

Merck

Sandra Poole

Sandra Poole

Chief Operating Officer

Mythic Therapeutics

Alex Cooke

Alex Cooke

CEO

Phase3

Christine Sheaffer

Christine Sheaffer

Vice President of Manufacturing & Supply

Spark Therapeutics

  • Is talent and workforce development in our industry changing? If so how and why?
  • What are the most important new technologies in manufacturing today?
  • What current factors are affecting speed of development and efficient manufacturing?
  • What Regulatory progress has been made and what future opportunities exist?
  • How can we improve the access of innovative medicines?
6:00pm

7:30am - 8:15am

8:15am - 8:20am

Opening Remarks and Important Announcements

8:20am - 8:30am

Chair’s Welcome Address

Charles L. Cooney

Charles L. Cooney

Robert T. Haslam Professor of Chemical Engineering, Emeritus, and Faculty Director, Emeritus Deshpande Center for Technological Innovation

MIT

8:30am - 9:05am

Manufacturing with an Agile and Flexible Mindset

Holger Weintritt

Holger Weintritt

EVP Head Pharmaceuticals Product Supply

Bayer

  • Building a strong manufacturing strategy that can cope with a constant changing environment
  • Highlighting the importance of flexibility in asset design to better adapt to market fluctuation and reach desired time to market speed
  • Becoming more agile and flexible in scaling-up new modalities (cell and gene therapies) to bring them at the required speed to patients
  • Adapting to a new operating model to bring flexibility and agility in resource and capability planning unleashing the full potential of an organization
9:05am - 9:40am

Strategic Expansion Roadmap: Fill & Finish Facilities for Global Growth

Flemming Dahl

Flemming Dahl

SVP Head of Product Supply Fill & Finish Expansions

Novo Nordisk

  • Exploring the strategies and considerations involved in building fill & finish facilities across a global manufacturing network
  • Discussing the importance of harmonization and global standards in pharmaceutical manufacturing and how we ensure consistency and quality across our facilities
  • Understanding the challenges and approaches in maintaining regulatory compliance when expanding fill & finish capabilities
  • Exploring the role of innovation and technology in enhancing efficiency and quality
9:45am - 10:20am

Panel: Optimizing Technical Operations: Best Practices for Manufacturing Next-Gen Medicines

  • Current trends and manufacturing strategies for next-generation medicines
  • Best in class practices for facility planning, CQV, operational readiness and startup
  • New innovative technologies on the horizon
9:45am - 10:20am

Data Doesn’t Lie – Digital Manufacturing ROI

Martin Smyth

Martin Smyth

SVP Go To Market Strategy

MasterControl

  • Why digitizing production records and connecting to other systems is needed to remain competitive 
  • The areas where digital systems have significant impact and how that translates to the bottom line
  • How digital systems can improve the work experience for operators
  • How to clearly demonstrate the ROI of a digital system
10:25am - 12:05pm
  • 10:30 am – 10:50 am: Meeting Slot 1/Networking
  • 10:55 am – 11:15 am: Meeting Slot 2/Networking
  • 11:20 am – 11:40 am: Meeting Slot 3/Networking
  • 11:45 am – 12:05 pm: Meeting Slot 4/Networking

These mutually agreed-upon conversations are arranged and facilitated by Executive Platforms staff to ensure attendees have valuable discussions about their top-of-mind questions, challenges, and opportunities.

12:10pm - 12:45pm

Manufacturing as a Strategic Enabler for Serial Innovation

Ciaran Brady

Ciaran Brady

Vice President, Manufacturing Science and Technology

Vertex Therapeutics

  • Sharing Vertex’s track record for serial innovation in manufacturing to create transformative medicines for people with serious diseases and high unmet medical needs
  • Highlighting Vertex’s success with small molecule continuous manufacturing
  • Transforming manufacturing in cell and genetic therapies for Sickle Cell Disease, Beta Thalassemia, and Type 1 Diabetes
  • Describing the specific technical innovations and breakthroughs that have been instrumental in Vertex’s manufacturing success
  • Emphasizing the importance of cross-functional collaboration to drive manufacturing innovations and deliver transformative medicines
12:10pm - 12:45pm

Proactivity – the Future of Quality

Anthony Mire-Sluis

Anthony Mire-Sluis

SVP Head of Global Quality

AstraZeneca

  • Using Human and Organizational Performance (HOP) in designing quality into the end to end supply processes and how to implement effectively
  • Adopting risk-based approaches to identify and mitigate potential issues, maintaining a focus on critical processes and regulatory compliance
  • Fostering a culture of continuous improvement, leveraging digital tools to optimize processes and enhance overall quality management
  • Establish a proactive approach to regulatory compliance and production effectiveness using appropriate problem solving and conducting regular self-assessments
12:10pm - 12:45pm

Navigating the Complexities of Gene Therapy Commercialization and Manufacturing

Ryan Bartock

Ryan Bartock

Head of Engineering, Technical & Digital

Spark Therapeutics

  • Scaling up gene therapy production, the challenges, solutions and real world examples exploring the next frontier of manufacturing and its significance
  • The future of external gene therapy development, meeting growing demand for advanced therapies
  • The impact and transformation of advanced technologies on improving efficiency and product quality
  • Exploring strategies for collaboration and partnerships for large scale gene therapy production
  • Regulatory challenges in gene therapy manufacturing
  • Case studies of successful external gene therapy commercialization and manufacturing models and discussing the future outlook of meeting the growing demand
12:45pm - 1:45pm

Executive Lunch Seating

12:45pm - 1:45pm

Explore this year’s themed lunch discussions led by industry leaders, where executives engage in focused conversations over a meal, discussing topics they’re passionate about alongside their peers.

Best Practices for Integrated Business Planning in Pharma: Leveraging Connected Planning to Drive Growth

Robert Honer, PMP CPIM

Robert Honer, PMP CPIM

Senior Director, Supply Chain Practice

Anaplan

Industry Trends, Challenges, and Opportunities in Process and Technology Platforms for the Commercialization of Gene Therapy Products

Christopher Klem

Christopher Klem

Sr. Director Global Manufacturing

AskBio

Knowledge Retention in a Time of High Turnover

Kari Borroel

Kari Borroel

Head of Operations Quality Learning & Development

AstraZeneca

Automation Technology to Unlock the Future of Cell Therapy Manufacturing

Paul Kopesky

Paul Kopesky

VP Cell Process Development

Beam Therapeutics

Lessons and Opportunities in Value Stream Mapping

Alok Bhatt

Alok Bhatt

Senior Director, Biologics Value Chain, Global Manufacturing & Supply

BMS

Supply Chain Revolution: Prioritizing Patients in Pharmaceutical Logistics

John Glavas

John Glavas

AVP External Manufacturing

Merck

Creating the Multi-Launch CTOs of the future: Who, How, & When?

Alex Cooke

Alex Cooke

CEO

Phase3

Modernizing the Pharma Quality System. What is It and Does It Drive Results?

Lisa Winstead

Lisa Winstead

Sr. Director - Site Quality Head

Resilience

Culture Transformation: from Compliance to Performance

Yana Collins

Yana Collins

Head of Quality Culture and Transformation

Sanofi

Leveraging Platform Processes for Efficient and Effective Gene Therapy Manufacturing

Christine Sheaffer

Christine Sheaffer

Vice President of Manufacturing & Supply

Spark Therapeutics

Rusty Shreve

Rusty Shreve

Director, Manufacturing Operations

Spark Therapeutics

Changing the Compliance Paradigm in Large, Global Companies

Peter Shearstone

Peter Shearstone

VP Global Quality & Regulatory Affairs

Thermo Fisher Scientific

1:45pm - 2:20pm

Driving Transformation in Quality to Meet the Needs of Our Customers

Robin Kumoluyi

Robin Kumoluyi

VP & Chief Quality Officer, J&J Innovative Medicine

Johnson & Johnson

  • Quality as a business driver by “Flipping the Ratio”
  • Transforming business growth through Proactive Quality
  • Preparing our organization for the future of Quality Assurance
2:25pm - 3:00pm

Accelerate Your Bench to Production Timeline by Collocating Research with Process Development and Pilot Scale Production

Peter Genest

Peter Genest

Head of Client Solutions

SmartLabs

Craig Beasley

Craig Beasley

Chief Technical Officer

Blue Rock Therapeutics

  • Facilitate tech transfers between teams
  • Transition from a PD lab to Pilot lab as business needs change
  • Ensure quality of pharmaceutical products
  • Improve your process as it evolves during optimization
2:25pm - 3:00pm

The Value of a Unified Life Sciences Solution in Pharma 4.0

Zillery Fortner

Zillery Fortner

Industry & Business Development Director

Honeywell

April VanDenDriessche

April VanDenDriessche

MES Technical Solutions Consultant

Honeywell

  • Manage the production process and quality in real time from order to batch release in one browser-based user interface visualizing real-time and historical data
  • Streamline collaboration between manufacturing and quality people and processes to maximize throughput and accelerate batch release
  • Digitize all direct batch execution (EBR) and execution related activities (Logbooks and Digital Procedures) to eliminate paper or unstructured electronic records where data is trapped
  • Take advantage of configurable functionality
  • Analyze and report on operational data in one place for a single source of the truth
  • Achieve measurable results in cost reduction, risk mitigation, and revenue opportunities
2:25pm - 3:00pm

From “Impossible” to Commercialization

Scott DeWire PhD

Scott DeWire PhD

US Head, Business Development & Licensing

Boehringer Ingelheim

Michael Kraich PhD

Michael Kraich PhD

Vice President of Global Project & Product Management BioXcellence

Boehringer Ingelheim

  • Boehringer Ingelheim BioXcellence™ demonstrates how effective collaboration in contract manufacturing can expedite the delivery of innovative medicines
  • Leveraging expertise in microbial development and manufacturing
  • Toolbox approach for a groundbreaking cancer vaccine platform, that was honored with European Inventor Award in 2022
  • Showcasing two perspectives from CMO and partner
  • The session will highlight the power of collaboration and innovation in the pharmaceutical industry
3:05pm - 4:15pm
  • 3:05 pm – 3:25 pm: Meeting Slot 5/Networking
  • 3:30 pm – 3:50 pm: Meeting Slot 6/Networking
  • 3:55 pm – 4:15 pm: Meeting Slot 7/Networking

These mutually agreed-upon conversations are arranged and facilitated by Executive Platforms staff to ensure attendees have valuable discussions about their top-of-mind questions, challenges, and opportunities.

4:20pm - 4:55pm

Becoming a “Best in Class” Supply Chain Network to Deliver More Medicines to More Patients, Faster

Catalina Vargas

Catalina Vargas

SVP Global Supply Chain

Bristol Myers Squibb

  • Fostering an efficient and agile supply chain network with a quality excellence and continuous improvement mindset
  • Delivering robust and reliable “patient need” signals to our network with minimal friction
  • Being seen as a trusted, visible, and resilient partner for our stakeholders
  • Developing engaged teams who lead with an enterprise mindset and lean into their functional expertise
  • Resulting in one highly synchronized, transparent and sustainable supply chain network that enables a competitive advantage
4:55pm - 5:30pm

Sanofi Manufacturing Transformation: Turning Science into Reality for Patients

Daniela Ottini

Daniela Ottini

SVP, Manufacturing and Supply Head of Specialty Care

Sanofi

  • Our new purpose: we chase the miracles of science to improve people’s lives
  • Our race to make available breakthrough treatments & vaccines for patients supported by diverse modalities: accelerate product launches and optimize our asset performance
  • Our ambition to develop a network of Factories of the Future
5:30pm - 5:35pm

Chair’s Closing Remarks

Charles L. Cooney

Charles L. Cooney

Robert T. Haslam Professor of Chemical Engineering, Emeritus, and Faculty Director, Emeritus Deshpande Center for Technological Innovation

MIT

5:35pm

6:30pm

7:30am - 8:20am

7:45am - 8:20am

Pioneering Manufacturing Automation Innovation with AI

Amy Doucette

Amy Doucette

Head of Business Operations

Applied Materials APG Pharma

Jordan Croteau

Jordan Croteau

Sr. Director, Manufacturing Operational and Engineering Technology

Moderna

  • Leveraging lessons learned from the semiconductor industry for tech-first companies
  • The journey of defining the high value problems and opportunities for personalized medicine
  • Optimizing productivity and quality for manufacturing resilience and sustainability
  • Speed to insights for “Right First Time”
  • Innovation enabling improvements in key achievement drivers
8:25am - 8:35am

Chair’s Opening Remarks

Charles L. Cooney

Charles L. Cooney

Robert T. Haslam Professor of Chemical Engineering, Emeritus, and Faculty Director, Emeritus Deshpande Center for Technological Innovation

MIT

8:35am - 9:10am

A Vision for the Future: Moderna’s Plans for mRNA Technology, Manufacturing and Scale

Jerh Collins

Jerh Collins

Chief Technical Operations and Quality Officer

Moderna

  • Pivoting fearlessly: How Moderna transitioned from a pandemic to an endemic market
  • Building for scale: Where the company is investing and partnering as it plans to launch up to 15 products in 5 years
  • Prioritizing culture: What it took to encode the company’s mindsets and unique culture
9:10am - 9:45am

Integrating Customer Centricity and Innovative Technology into a Forward-Looking Manufacturing & Compliance Strategy

Anil Sawant

Anil Sawant

SVP Global Quality Compliance

Merck

  • How are biology and patient needs influencing risk-based investment and networking structure in the manufacturing space?
  • Discussing route and location of administration, including MDCP considerations, components and suppliers, design standards
  • Exploring flexible facilities, integrated clinical launches, and capital risk avoidance in the quest to get fast to clinical and fast to respond
  • Understanding the need for early investment in platform changes. How is the emergence of ADCs, modality blurring, and market
  • How do we ensure quality, risk management and compliance processes are in lock step as our technology and platforms evolve
9:50am - 10:25am

Fireside Chat: Navigating Technological Advancements, Global Operations, and Supply Chain Innovation

Craig Beasley

Craig Beasley

Chief Technical Officer

Blue Rock Therapeutics

  • Exploring strategies for enhancing efficiency and reliability in the supply chain for cell therapy products, encompassing supply/demand planning, strategic sourcing, GMP purchasing, and external manufacturing
  • Delving into the evolution of manufacturing methodologies, focusing on cutting-edge technologies, automation, and adaptive processes to meet increasing demands and regulatory requirements
  • Discussing best practices, challenges, and considerations in establishing and managing facilities on a global scale, addressing regulatory compliance, operational excellence, and localization strategies
  • Highlighting innovative approaches to managing the drug supply chain, from clinical trials to commercialization, including advancements in logistics, temperature-controlled distribution, and risk mitigation strategies
9:50am - 10:25am

Advanced Manufacturing and Complex Biologic Products

Ingrid Markovic

Ingrid Markovic

Senior Science Advisor/CMC Lead

FDA

  • Grasping the significance of FDA-CBER’s oversight in pharma manufacturing, ensuring adherence to strict quality standards, safety measures, and ethical guidelines for global health and patient well-being
  • Discuss efforts to expedite development of products for small populations through increased use of accelerated approval
  • Review efforts toward global regulatory convergence
  • Summarize internal changes and external initiatives at FDA in support of expeditious product development
9:50am - 10:25am

Fireside Chat: Navigating Gene Therapy Commercialization: Trends, Challenges, and Opportunities in Process and Technology Platforms

Christopher Klem

Christopher Klem

Sr. Director Global Manufacturing

AskBio

  • Exploring leveraging partners and CDMOs for gene therapy commercialization’s focusing on scalability, quality and resilience
  • Discussing key regulatory hurdles in bringing gene therapy products to market, including FDA requirements, regulatory submission, and manufacturing process
  • Highlighting emerging technologies and platforms, considering advancements in viral vector manufacturing, gene editing techniques and cell therapy processes
  • Delving into supply chain complexities and examining strategies for mitigating risks, optimizing logistics and ensuring uninterrupted supply
  • Opportunities for collaboration and innovation to accelerate advancements in process optimization, technology development and ultimately patient access to life changing therapies
10:25am - 11:15am
  • 10:30 am – 10:50am: Meeting Slot 8/Networking
  • 10:55am – 11:15am: Meeting Slot 9/Networking

These mutually agreed-upon conversations are arranged and facilitated by Executive Platforms staff to ensure attendees have valuable discussions about their top-of-mind questions, challenges, and opportunities.

10:40am - 11:15am

Executive focus groups are informal moderated discussions among peers, held during networking breaks outside the summit agenda. No sign-up is required; delegates and speakers can join any group of interest.

Focus Group Panel: The Evolving Future of Quality – Signals, Trends and Lessons

Karin Ann Payne

Karin Ann Payne

Vice President Corporate Quality

Bristol Myers Squibb

Vaishali Shukla

Vaishali Shukla

VP Quality

Kite Pharma

Lisa Winstead

Lisa Winstead

Sr. Director - Site Quality Head

Resilience

11:20am - 11:55am

The CDMO of the Future

JR Humbert

JR Humbert

VP Quality

INCOG BioPharma Services

  • Learn how a CDMO can be a Customer-Driven Manufacturing Organization
  • How CDMOs can use digital infrastructure to make the experience from technology transfer all the way through lifecycle management more customer-focused
  • How CDMOs can partner to integrate the supply chain to simplify processes and increase reliability
  • How strategic investments by customers with CDMOs can create value for both customer and CDMO
11:20am - 11:55am

Reducing Unplanned Downtime Using Integrated Predictive Maintenance and Operation Teams Management for Steamlined Workflows, Reduced Operational Risk and Optimal Production

Ed Garibian

Ed Garibian

CEO

LLumin Inc.

Dennis Ladd

Dennis Ladd

Senior Sales Executive

Eschbach North America

  • Learn how using LLumin CMMS+ integrated with eschbach ShiftConnector, not only improve communication for operators in the clean room or control room, quality and maintenance but actually reduces mean time to repair (MTTR) levels: minimizing disruptions and safeguarding critical pharmaceutical operations
  • Gain keen preventive maintenance insights such as adding machine parameter and condition monitoring for increasing clarity with maintenance work order instructions and parts requirements among other benefits
  • Discover how to optimize maintenance department processes and elevate your Return on Asset (ROA) investment levels
  • Uncover how Artificial Intelligence (AI) can bring a new level of intelligence that can easily be adaptable to fit pharmaceutical company’s needs

 

11:20am - 11:55am

What Traits Should Biopharma Companies Look for When Partnering with Drug Substance CDMOs?

Jin Seok Hur

Jin Seok Hur

General Manager and Head of Technical Sales, US

Axplora US

Arul Ramadurai

Arul Ramadurai

Chief Commercial Officer (CCO)

Axplora

  • Best traits to look for when partnering with a CDMO, besides just capabilities and capacity
  • Best practices for discerning which CDMO’s are best for biopharma companies to partner with
  • Key steps for helping biopharma companies navigate complex sales processes with CDMOs
12:00pm - 12:35pm

Real-Time Release, a Distant Dream or Reality?

Olav Lyngberg

Olav Lyngberg

VP Innovation and Technology Deployment, Janssen Supply Chain

The Janssen Pharmaceutical Companies of Johnson & Johnson

  • Insight into J&J’s journey to implement real time multivariate analytics, PAT, modeling and feedback control
  • Achieving integrated quality objectives, reducing non-conformance, enhancing quality control, and enabling real time release
  • Integration of digitalization, data, and Quality By Design to intensify processes for flexible and modular manufacturing tailored to customer requirements in quality, price, quantity, and delivery
  • Exploring the lessons learnt from the real-time release journey and their alignment with J&J’s long-term vision of quality-driven progress
12:00pm - 12:35pm

How Do We “Stay Ahead of the Curve in an Increasingly Complex Regulatory World?”

Søren Thuesen Pedersen

Søren Thuesen Pedersen

Senior Director External Affairs, Regulatory Policy and Intelligence

Novo Nordisk

  • Discussing the growing regulatory complexity in the world of pharmaceutical quality and manufacturing.
  • How are new guidelines and regulators’ expectations changing?
  • Taking a process-based approach to impact assessment, and customizing a setup that identifies and acts on signals proactively
  • How do we involve the organization in a sustainable way in all of this (Bottom Up approach)Bringing a structured approach to your advocacy within your network of industry and trade organization connections
12:00pm - 12:35pm

A Digital Twin for Integrated mRNA Manufacturing

Dr. Richard Braatz

Dr. Richard Braatz

Edwin R. Gilliland Professor; Associate Faculty Director, MIT Center for Biomedical Innovation

MIT, Massachusetts Institute of Technology

  • Insights into the concept of digital twins and their application in integrated mRNA manufacturing, based on experience in advanced manufacturing and process data analytics
  • Exploring process modeling and control systems, focusing on their relevance to mRNA manufacturing and how digital twin technology can enhance efficiency and quality in this context
  • Discussing the potential of digital twins to revolutionize mRNA manufacturing, emerging trends, challenges, and the roadmap for further research and development in this field
  • Addressing the regulatory landscape surrounding mRNA manufacturing and how digital twin technology can facilitate compliance with regulatory requirements, ensuring product quality, safety and efficacy
12:35pm - 1:35pm

Executive Lunch Seating

12:35pm - 1:35pm

Explore this year’s themed lunch discussions led by industry leaders, where executives engage in focused conversations over a meal, discussing topics they’re passionate about alongside their peers.

CMC Considerations as We Revolutionize Cell Therapy Manufacturing

Matthew Conover

Matthew Conover

Sr. Director Cell Therapy CMC

BMS

Integrating Sustainability and Quality by Design to Improve Chances of Regulatory Success

Jonathan Tripp

Jonathan Tripp

Principal Scientist

Gilead Sciences

Michael O’Keefe

Michael O’Keefe

Director

Gilead

Navigating Quality 4.0: Initiating Your Path in Pharmaceutical Manufacturing

JR Humbert

JR Humbert

VP Quality

INCOG BioPharma Services

Keeping Pace with the Evolving Quality and Regulatory Trends in Cell Therapy

Scott Nichols

Scott Nichols

Director Quality

Kite Pharma

Realtime Manufacturing While Stabilizing The Workforce

Dottie Barr

Dottie Barr

SVP Manufacturing & Technical Operations

Lantheus

Achieving Speed to Market in an Evolving CGT landscape Via Laser Focus on Compliance, Systems and People

Elena Kichula

Elena Kichula

Sr. Director - Manufacturing, Science, and Technology and Process Engineering

Spark Therapeutics

Vaishal Patel

Vaishal Patel

QA Site Lead

Spark Therapeutics

1:35pm - 2:10pm

Maximizing Quality and Compliance: A Strategic Approach for Pharmaceutical Manufacturing

Nicolas Maldonado

Nicolas Maldonado

Executive Director, Global Quality Policies and Systems

Gilead Sciences

  • Introduction to the need for quality and compliance transformation and the impact of shifting regulatory landscapes on quality assurance and compliance
  • The role of advanced technologies in enhancing quality practices, ensuring data integrity and improved product safety and efficacy
  • Strategies for supplier quality management for maintaining consistency and building a culture of quality and compliance
  • Case studies highlighting quality driven practices that have led to improved transformation in enhancing quality practices
  • Real world success stories in transforming quality practices for the modern pharmaceutical landscape
2:15pm - 2:55pm

Panel: Looking Backwards, Looking Forwards: Maximizing Our Impact on the Future of Medicine

Joanne Beck

Joanne Beck

Chief Technology Officer

Aerium Therapeutics

Carlo de Notaristefani

Carlo de Notaristefani

Former Lead, Manufacturing & Supply Chain Advisor

Operation Warp Speed

Alex Cooke

Alex Cooke

CEO

Phase3

Pat Yang

Pat Yang

Vice Chairman & Co-Founder

Resilience, Inc.

  • How has this changed the CMC ecosystem, and are we overbuilding capacity again?
  • Avoiding the dangers of fragmentation. How should we better communicate, collaborate, and consolidate our best ideas so we all succeed?
  • Discussing the reasons to set up a new company today, and imagining how our business ecosystem will continue to grow and evolve
  • Debating which production platforms will best suit the newer modalities
  • Exploring the next steps for existing platforms like mAbs, ADC’s, mRNA: How do we efficiently serve giant markets such as Alzheimer’s indications, for example?
2:55pm - 3:00pm

Chair’s Closing Remarks

Charles L. Cooney

Charles L. Cooney

Robert T. Haslam Professor of Chemical Engineering, Emeritus, and Faculty Director, Emeritus Deshpande Center for Technological Innovation

MIT

Agenda Day Filter
Agenda Session Type Filter

Sessions From Previous Years

Download The Agenda PDF

"*" indicates required fields

Are you a delegate or sponsor?

By completing and submitting this form, you agree to receive marketing emails from Executive Platforms Inc. You can opt-out at any time by utilizing the unsubscribe link provided at the bottom of each email. All data collected will be handled in accordance with our Privacy Policy and Terms of Use.

Summit Floorplan

Sign Up For Our Newsletter

"*" indicates required fields

By completing and submitting this form, you agree to receive marketing emails from Executive Platforms Inc. You can opt-out at any time by utilizing the unsubscribe link provided at the bottom of each email. All data collected will be handled in accordance with our Privacy Policy and Terms of Use.